Pedro Sánchez‐Rovira

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

Hans von der Maase, Steen Werner Hansen, J.T. Roberts et al. · Journal of Clinical Oncology · 2000 · 2.3K citations · Full text

Medicine, Oncology, Pharmacology +11

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith, Marion Procter, Richard D. Gelber et al. · The Lancet · 2007 · 1.5K citations

Medicine, Oncology, Breast Oncology +15

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Miguel Martín, Álvaro Rodríguez-Lescure, A. Ruiz et al. · JNCI Journal of the National Cancer Institute · 2008 · 239 citations · Full text

Medicine, Oncology, Pharmacology +15